Effects of coadministration of the recombinant allergen from Tyrophagus putrescentiae (rTyr p 3) and oligo-deoxynucleotides CpG or FIP on the allergic asthma in mice model.

• Main Authors: Chen-Wei Hsu, 徐晨維
• Other Authors: Chau-Mei Ho
• Format: Others
• Language: zh-TW
• Published: 2009
• Online Access: http://ndltd.ncl.edu.tw/handle/08166195668644874443

碩士 === 國立陽明大學 === 臨床醫學研究所 === 97 === Allergic asthma appears to be one of the most common chronic diseases in recent year. When allergic patient expose to inhale allergens, like mite or pollen, may develop symptom like asthma. Tyrophagus putrescentiae (Tp) appears to be one of the common allergens in the environment and potentially causes allergic asthma in sensitized individuals. In the present study, we used Balb/c mice as an animal model to study the treatment of allergic asthma caused by Tp. The therapeutic agents contained recombinant protein of group 3 allergen in T. putrescentiae (rTyr p 3), which has molecular weight about 27 KDa and has been identified as major allergen. Oligodeoxynucleotides (CpG-ODNs) and fungal immunomodulatory protein (FIP) with the molecular weight 13 KDa were used as adjuvants. After intraperitoneal (IP) administra-tion of the crude extract of Tp, we found IgE and IgG1 increased in sensitized mice. Sensitized mice also showed airway hypersensitivity responses (AHR) to the intratracheal challenged with the crude extract, Tp. However, after local nasal immunotherapy(LNIT) with rTyr p 3 in conjunction with ODN (CpG) or FIP, the allergen-induced airway hyperreactivity in the sensitized mice was attenuated. The mice had polarized the cytokine balance towards Th1 cytokines, decreased IgE and IgG1, and increased IgG2a in serum. In these hyposensitized mice, there were decreased infiltration of inflammatory cells in lung, reduced eosinophils in BALF. After LNIT, IL-12 were increased and Th2 cytokines, IL-5 and IL-13, were decreased, and proflammatory cytokine, IL-17 and IL-23, were all decreased. The IL-10+ /Foxp3+/CD4+ CD25+ were also increased. These results suggest that combinating rTyr p 3 and CpG, or rTyr p 3 and FIP could upregulate Th1 cells and downregulate Th2 cells and may enhance activation Treg response. These results support that this kind of immunotherapy is an effective strategy for the treatment of allergic asthma.